{"id":20456,"date":"2025-01-02T19:49:06","date_gmt":"2025-01-02T11:49:06","guid":{"rendered":"https:\/\/flcube.com\/?p=20456"},"modified":"2025-01-02T19:49:09","modified_gmt":"2025-01-02T11:49:09","slug":"prime-gene-therapeutics-secures-over-rmb300-million-in-series-b-financing","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20456","title":{"rendered":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing"},"content":{"rendered":"\n

Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.<\/p>\n\n\n\n

Funding Allocation for Clinical Studies and Pipeline Expansion<\/strong>
The proceeds from this financing round will be directed towards the Phase III clinical studies for the company’s core product, pumecitinib gel, which is designed to treat mild to moderate atopic dermatitis (AD) in adults and adolescents. Additionally, the funds will support the market filing for pumecitinib gel, the expansion of its therapeutic indications, and the clinical advancement of other products within Prime Gene’s pipeline.<\/p>\n\n\n\n

Plans for Initial Public Offering<\/strong>
Prime Gene Therapeutics is also planning an initial public offering on the Beijing Stock Exchange, marking a significant step in the company’s growth and development. This move is expected to further bolster the company’s financial position and support its ongoing research and development efforts in the field of immune inflammatory diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory…<\/p>\n","protected":false},"author":1,"featured_media":20459,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,20,3023],"class_list":["post-20456","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-finance","tag-prime-gene-therapeutics"],"yoast_head":"\nPrime Gene Therapeutics Secures Over RMB300 Million in Series B Financing - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20456\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing\" \/>\n<meta property=\"og:description\" content=\"Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20456\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-02T11:49:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-02T11:49:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing\",\"datePublished\":\"2025-01-02T11:49:06+00:00\",\"dateModified\":\"2025-01-02T11:49:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456\"},\"wordCount\":204,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0216.png\",\"keywords\":[\"Auto-immune\",\"Finance\",\"Prime Gene Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20456#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20456\",\"name\":\"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0216.png\",\"datePublished\":\"2025-01-02T11:49:06+00:00\",\"dateModified\":\"2025-01-02T11:49:09+00:00\",\"description\":\"Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20456\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0216.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0216.png\",\"width\":1080,\"height\":607,\"caption\":\"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20456#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing - Insight, China's Pharmaceutical Industry","description":"Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20456","og_locale":"en_US","og_type":"article","og_title":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing","og_description":"Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.","og_url":"https:\/\/flcube.com\/?p=20456","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-02T11:49:06+00:00","article_modified_time":"2025-01-02T11:49:09+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20456#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20456"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing","datePublished":"2025-01-02T11:49:06+00:00","dateModified":"2025-01-02T11:49:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20456"},"wordCount":204,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20456#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png","keywords":["Auto-immune","Finance","Prime Gene Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20456#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20456","url":"https:\/\/flcube.com\/?p=20456","name":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20456#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20456#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png","datePublished":"2025-01-02T11:49:06+00:00","dateModified":"2025-01-02T11:49:09+00:00","description":"Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory diseases, has reportedly raised over RMB300 million (USD41 million) in a Series B financing round. The investment was led by a consortium of prominent financial backers, including Beijing Medical and Health Industry Investment Fund, E-town Capital, BSTIG, BSD, and ZQET Group.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20456#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20456"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20456#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png","width":1080,"height":607,"caption":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20456#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0216.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20456"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20456\/revisions"}],"predecessor-version":[{"id":20460,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20456\/revisions\/20460"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20459"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}